DIA.MI - DiaSorin S.p.A.

Milan - Milan Delayed Price. Currency in EUR
+0.72 (+0.73%)
At close: 05:35PM CEST
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
Previous Close98.12
Bid98.98 x 0
Ask99.00 x 0
Day's Range97.90 - 99.24
52 Week Range94.28 - 143.80
Avg. Volume166,602
Market Cap5.29B
Beta (5Y Monthly)0.13
PE Ratio (TTM)28.90
EPS (TTM)3.42
Earnings DateJul 27, 2023
Forward Dividend & Yield1.10 (1.12%)
Ex-Dividend DateMay 22, 2023
1y Target Est108.70
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for DIA.MI

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin

      Sale of assets related to Flow Cytometry & Imaging (FCI) Business UnitAcquisition will expand Cytek’s product portfolio to include imaging and menu-based application driven flow cytometry to provide full cell analysis solutions to its customersTransaction is in line with DiaSorin’s strategic priorities communicated to the market after Luminex acquisitionEmployees associated with commercial, operations, R&D and supporting functions expected to join Cytek SALUGGIA, Italy and FREMONT, Calif., Feb.